EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Clinical trials for EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS explained in plain language.
Never miss a new study
Get alerted when new EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS trials appear
Sign up with your email to follow new studies for EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for rare blood vessel disease
Disease control OngoingThis study tests a drug called tezepelumab in 42 adults with EGPA, a rare disease that causes inflammation in blood vessels and can damage organs. The goal is to see if the drug helps patients reach remission, meaning no active disease and low steroid use. Participants receive ei…
Matched conditions: EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Proteomics may unlock key clues to mepolizumab success in rare lung disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to find biological markers in blood, saliva, and sputum that can predict how well patients with EGPA (a rare inflammatory disease) and severe asthma respond to the drug mepolizumab. Researchers will analyze proteins in these samples before and after treatment to u…
Matched conditions: EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE4 • Sponsor: Azienda Ospedaliero Universitaria di Cagliari • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC